Gerhard Zugmaier

Gerhard Zugmaier is the clinical development leader who orchestrated blinatumomab's journey from Micromet through Amgen acquisition to FDA approval. As Executive Medical Director at Amgen Research Munich, he has overseen the global BiTE clinical development portfolio spanning adult and pediatric ALL, NHL, and expansion to solid tumors. His Blood 2015 first authorship on blinatumomab pharmacokinetics and his leadership of the RIALTO and expansion studies have established optimal dosing strategies. With 212 publications and 12,832 citations, Zugmaier represents the critical industry link translating BiTE platform innovations into approved therapies.

Gerhard Zugmaier博士是临床开发负责人，他协调了blinatumomab从Micromet到安进收购再到FDA批准的整个历程。作为安进慕尼黑研究中心执行医学总监，他监督了涵盖成人和儿童ALL、NHL及扩展到实体瘤的全球BiTE临床开发组合。他在Blood 2015上作为第一作者发表的blinatumomab药代动力学论文以及领导RIALTO和扩展研究，建立了最佳剂量策略。凭借212篇出版物和12,832次引用，Zugmaier代表了将BiTE平台创新转化为批准疗法的关键产业纽带。